| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hsien-Yuan Lane, Cheng-Chun Lee, Yi-Ching Liu, Wen-Ho Chan. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. Pharmacogenomics. vol 6. issue 2. 2006-09-28. PMID:15882132. |
risperidone and other newer atypical antipsychotics are becoming the mainstay for schizophrenia treatment. |
2006-09-28 |
2023-08-12 |
Not clear |
| Hsien-Yuan Lane, Cheng-Chun Lee, Yi-Ching Liu, Wen-Ho Chan. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. Pharmacogenomics. vol 6. issue 2. 2006-09-28. PMID:15882132. |
recent studies suggest that the 5-hydroxytryptamine receptor 2a (5-ht2a) gene (htr2a) t102c and g-1438a polymorphisms may influence treatment response of risperidone or olanzapine for schizophrenia's negative symptoms (e.g., blunted affect and social withdrawal). |
2006-09-28 |
2023-08-12 |
Not clear |
| Gabriel Rubio, Isabel Martínez, Guillermo Ponce, Miguel Angel Jiménez-Arriero, Francisco López-Muñoz, Cecilio Alam. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 51. issue 8. 2006-09-26. PMID:16933590. |
long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. |
2006-09-26 |
2023-08-12 |
human |
| Gabriel Rubio, Isabel Martínez, Guillermo Ponce, Miguel Angel Jiménez-Arriero, Francisco López-Muñoz, Cecilio Alam. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 51. issue 8. 2006-09-26. PMID:16933590. |
this study aimed to compare the efficacy of long-acting risperidone and zuclopenthixol in subjects with schizophrenia and substance abuse. |
2006-09-26 |
2023-08-12 |
human |
| Philip J Tyson, Keith R Laws, Kenneth A Flowers, Agi Tyson, Ann M Mortime. Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics. Psychiatry and clinical neurosciences. vol 60. issue 4. 2006-09-20. PMID:16884450. |
comparisons were done for matched schizophrenia patients who were on antipsychotics with (i) an affinity for multiple receptors (olanzapine, clozapine, quetiapine) versus those that have preferential affinity for dopamine receptors (risperidone, amisulpride); and patients on medication with (ii) a high affinity for serotonin (5ht-2a) receptors (risperidone, olanzapine, clozapine) versus those with a low (or no) affinity for 5ht-2a receptors (quetiapine, amisulpride). |
2006-09-20 |
2023-08-12 |
Not clear |
| Jean-Michel Azorin, Nathalie Strub, Henrik Lof. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. International clinical psychopharmacology. vol 21. issue 1. 2006-09-19. PMID:16317317. |
a double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. |
2006-09-19 |
2023-08-12 |
Not clear |
| Thomas A Hardy, Eva Marquez, Ludmila Kryzhanovskaya, Cindy C Taylor, Patrizia Cavazzon. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. Journal of clinical psychopharmacology. vol 26. issue 4. 2006-09-18. PMID:16855460. |
cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. |
2006-09-18 |
2023-08-12 |
Not clear |
| Thomas A Hardy, Eva Marquez, Ludmila Kryzhanovskaya, Cindy C Taylor, Patrizia Cavazzon. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. Journal of clinical psychopharmacology. vol 26. issue 4. 2006-09-18. PMID:16855460. |
we compared fasting lipids and other metabolic parameters in 211 normoglycemic patients meeting the dsm-iv diagnosis of schizophrenia or schizoaffective disorder undergoing continuous treatment with olanzapine, risperidone, or typical antipsychotics for at least 1 year. |
2006-09-18 |
2023-08-12 |
Not clear |
| Herbert Y Meltzer, William V Bob. Interpreting the efficacy findings in the CATIE study: what clinicians should know. CNS spectrums. vol 11. issue 7 Suppl 7. 2006-09-08. PMID:16816796. |
the clinical antipsychotic trials of intervention effectiveness (catie) schizophrenia trial was an effectiveness/"pragmatic" clinical trial designed to compare the efficacy, tolerability, and cost-effectiveness of four atypical antipsychotics (olanzapine, quetiapine, risperidone and ziprasidone) and a conventional antipsychotic (perphenazine) for an 18-month period in patients with schizophrenia. |
2006-09-08 |
2023-08-12 |
Not clear |
| Henry A Nasralla. Metabolic findings from the CATIE trial and their relation to tolerability. CNS spectrums. vol 11. issue 7 Suppl 7. 2006-09-08. PMID:16816798. |
the clinical antipsychotic trials of intervention effectiveness (catie) schizophrenia study assessed the efficacy of the atypical antipsychotics olanzapine, quetiapine, risperidone, and ziprasidone relative to the conventional drug perphenazine. |
2006-09-08 |
2023-08-12 |
Not clear |
| Rael D Strous, Marina Kupchik, Suzana Roitman, Sima Schwartz, Noach Gonen, Roberto Mester, Abraham Weizman, Baruch Spiva. Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. Human psychopharmacology. vol 21. issue 4. 2006-08-31. PMID:16783815. |
comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. |
2006-08-31 |
2023-08-12 |
Not clear |
| Rael D Strous, Marina Kupchik, Suzana Roitman, Sima Schwartz, Noach Gonen, Roberto Mester, Abraham Weizman, Baruch Spiva. Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. Human psychopharmacology. vol 21. issue 4. 2006-08-31. PMID:16783815. |
risperidone, olanzapine, and clozapine are three atypical antipsychotic medications commonly used in the management of chronic schizophrenia. |
2006-08-31 |
2023-08-12 |
Not clear |
| Rael D Strous, Marina Kupchik, Suzana Roitman, Sima Schwartz, Noach Gonen, Roberto Mester, Abraham Weizman, Baruch Spiva. Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. Human psychopharmacology. vol 21. issue 4. 2006-08-31. PMID:16783815. |
one hundred thirty-one patients (76 m, 55 f) with dsmi-v schizophrenia or schizoaffective disorder were treated with risperidone (n = 38), olanzapine (n = 38), or clozapine (n = 55). |
2006-08-31 |
2023-08-12 |
Not clear |
| Kate X Zhong, Dennis E Sweitzer, Robert M Hamer, Jeffrey A Lieberma. Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. The Journal of clinical psychiatry. vol 67. issue 7. 2006-08-30. PMID:16889453. |
comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. |
2006-08-30 |
2023-08-12 |
Not clear |
| Kate X Zhong, Dennis E Sweitzer, Robert M Hamer, Jeffrey A Lieberma. Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. The Journal of clinical psychiatry. vol 67. issue 7. 2006-08-30. PMID:16889453. |
to compare the efficacy and tolerability of quetiapine and risperidone in the treatment of schizophrenia. |
2006-08-30 |
2023-08-12 |
Not clear |
| Hitoshi Takahashi, Keizo Yoshida, Jun Ishigooka, Hisashi Higuch. Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial. Progress in neuro-psychopharmacology & biological psychiatry. vol 30. issue 6. 2006-08-23. PMID:16759777. |
switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial. |
2006-08-23 |
2023-08-12 |
Not clear |
| Hitoshi Takahashi, Keizo Yoshida, Jun Ishigooka, Hisashi Higuch. Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial. Progress in neuro-psychopharmacology & biological psychiatry. vol 30. issue 6. 2006-08-23. PMID:16759777. |
the purpose of this study was to assess the effect of switching to risperidone in the treatment of first-episode schizophrenia who had failed to respond to an initial-prescribed antipsychotic, olanzapine. |
2006-08-23 |
2023-08-12 |
Not clear |
| L N Gorobet. Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders. Bulletin of experimental biology and medicine. vol 140. issue 6. 2006-08-22. PMID:16848233. |
plasma prolactin concentration was measured in patients with schizophrenia and schizoaffective disorders receiving therapy with risperidone, olanzapine, and quetiapine and compared with the corresponding parameter in patient receiving typical neuroleptic drug haloperidol. |
2006-08-22 |
2023-08-12 |
Not clear |
| Paul H Lysake. Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks. Evidence-based mental health. vol 9. issue 3. 2006-08-11. PMID:16868190. |
olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks. |
2006-08-11 |
2023-08-12 |
Not clear |
| Enrique Alvarez, Antonio Ciudad, José Manuel Olivares, Manuel Bousoño, Juan Carlos Góme. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. Journal of clinical psychopharmacology. vol 26. issue 3. 2006-08-10. PMID:16702888. |
a randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. |
2006-08-10 |
2023-08-12 |
Not clear |